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of l-arginine on the urine flow rate was significantly less pro-Effect of L-arginine infusion in normotensive subjects with and
nounced in subjects with a family history of severe hyperten-without a family history of hypertension.
sion, which may indicate a tubular disturbance in hypertension.Background. Experimental studies have shown that nitric
oxide (NO) generation in the kidney from l-arginine partici-
pates in the regulation of renal function. Our purpose was to
study the effect of infusion of l-arginine (1, 5, and 10 mg/kg/min)
There is evidence that nitric oxide (NO) plays an im-on blood pressure (BP), renal hemodynamics, and urinary ex-
portant role in the regulation of systemic and renal he-cretion of sodium and albumin in normotensive subjects with
a family history of either severe hypertension (FHSH, N 5 17) modynamics [1, 2]. NO, which is formed from its sub-
or mild hypertension (FHMH, N 5 20) and in control subjects strate l-arginine in presence of NO synthase in the
(N 5 18) without a hereditary predisposition for hypertension. endothelium, increases cGMP in the vascular smoothMethods. The glomerular filtration rate (GFR) and renal
muscle cells leading to vasodilation [3, 4].plasma flow (RPF) were measured by renal clearances of Cr51
An impaired endothelium-dependent vascular relax-ethylenediaminetetraacetic acid and paramino-hippurate. Re-
nal tubular reabsorption of sodium was estimated by lithium ation in hypertension has been reported by several inves-
clearance. To evaluate the effect of l-arginine infusion on the tigators, and this mechanism has been suggested as a
l-arginine/NO pathway, we measured the NO-metabolite ni- pathogenetic mechanism in primary hypertension [5, 6].trate in plasma, and urinary excretion of cGMP, the second
In salt-sensitive hypertensives, sodium chloride loadingmessenger of NO. The derivative at an l-arginine dose of 7.5
reduced the ability of l-arginine to produce NO in themg/kg/min was used as a measure of sensitivity to l-arginine.
Results. There was no difference in baseline systolic BP be- endothelium of the renal vasculature [7]. An intact NO
tween the groups, but diastolic BP was significantly higher in system is also a prerequisite for an appropriate urinary
FHSH compared with control subjects (P , 0.05). l-arginine
excretion of a salt load [8], but humans do not mirrorcaused a significant increase in urine flow, urinary excretion
rats in this regard (abstract; Schmidt et al, J Am Socof albumin and sodium, and lithium clearance in all groups.
FHSH showed a significantly decreased sensitivity to l-arginine Nephrol 9:330A 1998). An infusion of l-arginine can
with respect to urine flow rate (P 5 0029) compared with influence the glomerular filtration rate (GFR) and renal
FHMH and control subjects. l-arginine caused a significant plasma flow (RPF) differently in normotensive [9] and
decrease in the GFR in FHSH (P , 0.02) and control subjects
hypertensive subjects [7, 9, 10]. It increased urinary so-(P , 0.001), but in FHMH, the decrease did not reach statistical
dium excretion in fluid-loaded subjects [10] and in hyper-significance (P 5 0.097). There was no difference in sensitivity
to l-arginine with respect to BP, RPF, or GFR between the tensive patients on an unrestricted sodium diet [11].
three groups. In all patients, there was a significant positive l-Arginine can, however, influence urinary sodium ex-
relationship between D urine flow rate or D urinary sodium cretion by another mechanism, which may not be associ-
excretion and D GFR during infusion of l-arginine (P 5 0.003
ated with NO generation in the kidney. It stimulatesand P 5 0.03, respectively). Plasma nitrate and urinary cGMP
insulin secretion, which increases tubular sodium reab-decreased in all groups during the l-arginine infusion.
Conclusion. l-Arginine infusion in normotensive subjects sorbtion in the distal nephron [12, 13].
caused an enhanced urine flow rate and urinary sodium and One way to study pathophysiological mechanisms in
albumin excretion and a slight reduction in GFR. The effect the development of hypertension is to investigate normo-
tensive relatives of patients with established hyperten-
sion, who run an increased risk of developing high bloodKey words: nitric oxide, renal hemodynamics, sodium excretion, famil-
ial hypertension, high blood pressure. pressure (BP) in the future.
We have previously demonstrated that such individu-Received for publication January 28, 1999
als disclose a blunted response to an intravenous saltand in revised form June 8, 1999
Accepted for publication June 16, 1999 load despite a more pronounced BP rise during the salt
load [14] and, in addition, that they exhibit an increased 1999 by the International Society of Nephrology
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sensitivity to angiotensin II in the renal vasculature [15] were registered on a Mingograph 82 (Siemens-Elema,
Stockholm, Sweden). The mean arterial BP was calcu-and to insulin in the renal tubules [16].
The aim of this study was to evaluate whether normo- lated as one third of the pulse pressure plus the diastolic
BP. This method of noninvasive BP measurement hastensive subjects with a positive family history of hyper-
tension differed from individuals without a family history been evaluated during simultaneously performed intra-
arterial BP measurements and has been found to beof hypertension with respect to the effect of an arginine
infusion on renal hemodynamics and the tubular han- reliable [19].
dling of sodium, and if so, whether or not this difference
Body weightwas mediated by an effect on the NO system.
Body weight was measured with the subjects lightly
dressed without shoes, using a level balance, to the near-
METHODS
est 0.1 kg. Body height was measured to the nearest
Study groups 0.5 cm. Body mass index was calculated as the body
weight (kg)/body height (m2).This study was approved by the Ethics Committee of
the Faculty of Medicine, University of Gothenburg, and
Renal hemodynamicsan informed consent was given prior to the investigation.
In the study, young normotensive men (mean age 31 Renal plasma flow and GFR were measured as the
paraminohippurate (PAH) and Cr51 ethylenediaminetet-years, range 25 to 35 years) with a positive family history
of mild (N 5 20) and severe hypertension (N 5 17) raacetic acid (Cr-EDTA) clearances, respectively. The
technique of continuous infusion and urine collectionwere investigated. A positive family history of severe
hypertension was defined as a father or mother with at was used.
The patients initially received a priming dose ofleast five years of treatment of primary hypertension
requiring three or more antihypertensive drugs, alterna- Cr-EDTA (0.6 multiplied by body surface area equals
megabequerel) and PAH (0.04 multiplied by weight/mltively treated with two antihypertensive drugs and having
diastolic BP above 100 mm Hg. A positive family history 20% solution), followed by an intravenous infusion (both
at a rate of 0.83 ml/min) to produce a plasma concentra-of mild hypertension was defined as a father or mother
with at least five years of antihypertensive treatment tion of 500 counts/min per ml and 50 to 100 mmol/liter,
respectively. The subjects were initially hydrated withwith only one antihypertensive drug and a BP below
140/90 mm Hg on treatment. All subjects with a positive tap water (10 ml/kg body wt) to ensure diuresis. When
the urine flow was established, the priming doses offamily history of hypertension were recruited from hy-
pertensive subjects in our outpatient hypertension unit Cr-EDTA and PAH were given. The equilibration pe-
riod (45 min) started when the subject had emptied his(Sahlgrenska University Hospital, Gothenburg, Sweden)
[17]. No subject was on nitrate or drugs that might influ- bladder. The patients were supine throughout the study
but were allowed to stand up to void for each urineence tubular reabsorptive capacity, and everyone had
normal renal function. Control subjects with a negative collection.
This procedure resulted in a complete bladder empty-family history of hypertension (N 5 18) were matched
for age and recruited from normotensive patients in- ing according to ultrasound examination. Thereafter, two
30-minute baseline periods followed in which the subjectcluded in the Gothenburg Preventive Trial [18].
emptied his bladder at the end of each period. Between
Protocol the periods, they drank the same volume of water as
that of urine passed in the preceding period. These twoAll subjects were asked to avoid heavy physical exer-
cise on the day before the study. After an overnight fast, urine portions were pooled for the renal hemodynamic
assessment. Plasma and urine were assayed for PAH andthey arrived at the Wallenberg laboratory for cardiovas-
cular research at 7:30 am. Cr-EDTA. Clearance values were expressed per 1.73 m2
body surface area.They were fitted with one venous catheter, and the
experimental procedure was started at approximately When the two baseline periods had been completed,
the arginine infusion started and three 40-minute clear-8:00 a.m. Throughout the investigation, the patients re-
mained in a comfortable semirecumbent position (except ance periods with increasing concentration of arginine
(1, 5, and 10 mg/kg/min) followed.when voiding).
In the time control study, 0.9% sodium chloride was
Blood pressure given instead of l-arginine.
The BP was measured by means of an automatically
Renal tubular sodium reabsorptioninflated and deflated rubber cuff (12 3 35 cm). Korotkoff
V was taken as diastolic BP. Signals from a sound micro- At 9:00 p.m. the day before each study day, 600 mg
(16.2 mmol) of lithium (Li) carbonate was given orally.phone placed over the brachial artery and cuff pressure
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Table 1. Clinical data in normotensive subjects with positive familyBlood samples were drawn from the left antecubital cath-
history of severe hypertension (FHSH, N 5 17), with positive
eter at 10:00 a.m. the next day and then every clearance family history of mild hypertension (FHMH, N 5 20)
and in normotensive control subjects (C, N 5 18)period for analysis of serum Na and Li. Urine samples
were also collected and analyzed for Na and Li. The FHSH FHMH C
mean serum values for each clearance period were used
Age years 3161 32 61 3161
in calculations of renal clearance (ml/min). Systolic blood pressure
mm Hg 12563 127 63 12663Based on the assumption that Li is absorbed solely in
Diastolic blood pressurethe proximal tubules and to the same degree as Na and
mm Hg 8062a 7562 7561
water, Li clearance (CLi) equals the output of isotonic Heart rate beats/min 6562 66 62 6863
Weight kg 8563 83 63 8463fluid from the proximal tubule [20]. Plasma and urinary
Body mass index kg/m2 2661 24 61 2661concentrations of lithium were measured by atomic ab-
a P , 0.05sorption and sodium concentrations by flame photometry.
Analysis of nitrate in plasma
Blood samples (5 ml) were collected in heparin tubes.
use of the Kruskal–Wallis test with respect to sensitivityPlasma was separated by centrifugation for 10 minutes
to arginine for each one of the variables. By the use ofat 1500 3 g. The samples were stored at 2208C until
Fisher’s test for paired comparisons, it was testedanalysis. Nitrate in plasma samples was analyzed with a
whether the derivatives reflecting sensitivity were sig-gas chromatography/mass spectrometry (GC/MS) method
nificantly different from zero [23].[21], which has been further developed and has been
described previously [22].
Briefly, a known amount of plasma sample was added RESULTS
with a known amount of K15NO32 (Sigma Chemical Co., Some clinical data of the subjects are shown in Table 1.
St Louis, MO, USA) as internal standard. Endogenous
There was no difference in baseline systolic BP or heart
and 15N-labeled nitrate in the samples was converted to
rate between the three groups, but diastolic BP was sig-nitrobenzene. A portion of the sample was injected into
nificantly higher in FHSH as compared with control sub-a Varian 3400 gas chromatograph equipped with a XTi-5
jects. FHMH did not differ from control subjects. Thecapillary column. It was connected to a Varian Saturn II
l-arginine infusion caused a significant decrease in dia-mass spectrometer, selective monitoring of mass equiva-
stolic BP in FHSH (P , 0.01) and FHMH (P , 0.05)lent (m/e) 124 for endogenous nitrate and m/e 125 for
but not in control subjects (P 5 0057). There was, how-the 15N-labeled internal standard. The detection limit for
ever, no significant difference in the sensitivity toendogenous nitrate was 0.1 Tmol/liter, and the variation
l-arginine, measured as the derivative at an argininecoefficient was below 10%.
dose 5 7.5 mg, between the three groups (Table 4).
There was no difference in renal hemodynamics, urineOther assays
flow rate, or urinary excretion of sodium and albuminCommercial radioimmunoassays (RIAs) were used for
between the three groups at baseline (Table 2).determination of plasma insulin (Phadebas insulin kit;
l-Arginine caused a significant increase in the urinePharmacia, Stockholm, Sweden), plasma renin activity
flow rate, urinary excretion of albumin and sodium, and(PRA; Renin-RIA bead; Abbot Diagnostics Division,
lithium clearance in all groups (Table 2). FHSH showedSouth Pasadena CA, USA), and urine cGMP (Amer-
a significantly decreased sensitivity to l-arginine withsham, UK) and urine albumin (Pharmacia & Upjohn,
respect to urine flow (P 5 0029) compared with FHMHUppsala, Sweden).
and control subjects.
Statistics l-Arginine also caused a significant decrease in the
GFR in FHSH (P , 0.02) and control subjects (P ,Standard methods were used for calculations of means
0001), but in FHMH, the decrease did not reach statisti-and sem. The derivative at an arginine dose 5 7.5 mg/kg/
cal significance (P 5 0097; Table 3).min for the fitted curve of each individual was deter-
There was no difference in sensitivity to l-argininemined for each variable. The derivative could be consid-
with respect to the effect on GFR between the threeered as a measure of sensitivity to arginine. In the case
groups. Concerning RPF, there was a significant differ-of a linear regression function, the derivative is constant
ence in the sensitivity to l-arginine between the threefor all doses.
groups (Table 4).Linear regression was used except for three variables,
There was no difference in PRA or the plasma insulinurinary excretion of sodium, urinary albumin excretion,
concentration between the three groups at baseline orand systolic BP, where the quadratic fit was significantly
better. The three hereditary groups were compared by during the l-arginine infusion. Plasma nitrate and urinary
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Table 2. Effect of l-arginine infusion on renal hemodynamics, tubular handling of sodium and plasma renin activity (PRA) in normotensive
subjects with family history of severe hypertension (FHSH, N 5 17), with family history of mild hypertension (FHMH, N 5 20)
and in subjects without family history of hypertension (C, N 5 18)
l-arginine infusion mg/kg/min
Baseline 1 5 10 P value
Renal plasma flow FHSH 559622 552621 549623 530626 NS
ml/min FHMH 541621 547621 579620 573615 NS
C 542624 539618 543621 531624 NS
Glomerular filtration FHSH 10463 10463 10063 9364 20.014
rate ml/min FHMH 10363 10463 10664 9862 NS
C 10563 10362 10563 9463 20.001
Filtration fraction FHSH 0.1960.01 0.1960.01 0.1960.01 0.1860.01 20.020
% FHMH 0.1960.01 0.1960.01 0.1860.01 0.1760.01 20.001
C 0.2060.01 0.2060.01 0.1960.01 0.1860.01 20.021
Urine flow rate FHSH 11.6 60.6 12.360.8 13.260.7 12.560.9 NS
ml/min FHMH 11.060.6 12.260.8 13.860.5 15.060.9 0.001
C 12.260.5 11.660.6 13.060.8 14.260.9 0.002
Sodium excretion FHSH 0.2960.03 0.2960.02 0.2860.02 0.4660.05 0.001
mmol/min FHMH 0.2860.02 0.2960.03 0.3260.03 0.5560.07 0.001
C 0.3160.03 0.2960.03 0.3360.04 0.5760.07 0.001
Lithium clearance FHSH 33.061.8 32.761.6 33.361.8 38.462.0 0.005
ml/min FHMH 32.361.4 31.761.5 35.461.5 38.861.8 0.001
C 32.962.1 30.861.9 34.461.6 38.861.8 0.001
Fractional lithium FHSH 3261 3161 3361 4262 0.001
excretion % FHMH 3161 3161 3361 3962 0.001
C 3162 3062 3362 4161 0.001
PRA FHSH 1.160.2 0.960.1 0.960.1 0.860.1 20.026
ng/AI/ml 3 hr FHMH 1.460.1 1.060.1 1.060.1 1.060.1 20.001
C 1.560.2 1.060.1 1.060.1 0.960.1 20.007
Data are given as mean 6 sem.
By use of Fisher’s test for paired comparisons it was tested whether the derivatives reflecting sensitivity to l-arginine were significantly different from zero. Two-
sided P values are given with a sign 1 or 2 indicating whether the variable tended to increase (1) or decrease (2) with a higher dose of l-arginine. P , 0.05 was
considered significant.
Table 3. Effect of l-arginine infusion on blood pressure, plasma insulin and nitrate concentrations, erythrocyte volume fraction and urinary
excretion of cGMP and albumin in subjects with family history of severe hypertension (FHSH, N 5 17), with family history of mild
hypertension (FHMH, N 5 20) and in subjects without family history of hypertension (C, N 5 18)
l-arginine infusion mg/kg/min
Baseline 1 5 10 P value
SBP mm Hg FHSH 12563 128 62 126 63 125 63 NS
FHMH 12763 129 62 128 62 128 63 NS
C 126 62 128 62 128 62 128 63 NS
DBP mm Hg FHSH 8062 81 63 77 63 73 63 20.001
FHMH 7562 77 62 75 62 72 62 20.026
C 7561 77 61 74 61 72 62 NS
Plasma insulin concentration FHSH 1162 8 61 1862 25 65 0.001
mU/liter FHMH 1663 8 61 1762 24 63 0.001
C 1462 8 61 1863 21 63 0.001
Plasma nitrate lmol/liter FHSH 3262 29 61 29 62 26 61 20.006
FHMH 4065 33 63 33 63 32 63 20.046
C 3163 30 61 28 62 26 62 20.027
EVF % FHSH 43.460.6 43.2 60.6 42.7 60.6 42.5 60.6 NS
FHMH 42.360.5 42.1 60.6 41.6 60.6 41.3 60.6 NS
C 42.9 60.5 42.8 60.6 42.5 60.6 42.0 60.6 NS
Urinary cGMP excretion FHSH 5665 48 64 49 65 48 64 NS
pmol/min FHMH 5667 48 64 49 65 48 67 NS
C 5466 46 64 49 65 46 65 0.019
Urinary albumin excretion FHSH 1062 8 62 1161 53 66 0.001
lg/min FHMH 1563 12 62 17 63 72 67 0.001
C 961 7 61 1061 55 68 0.002
Mean 6 sem is given. By use of Fisher’s test for paired comparisons it was tested whether the derivatives reflecting sensitivity to l-arginine were significantly
different from zero. Two-sided P values are given with a sign 1 or 2 indicating whether the variable tended to increase (1) or decrease (2) with a higher dose of
l-arginine. P , 0.05 was considered significant.
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; EVF, erythrocyte volume fraction.
Herlitz et al: Effect of l-arginine on renal function1842
Table 4. Difference in sensitivity to l-arginine between the groups
with family history of severe hypertension (FHSH, N 5 17),
with family history of mild hypertension (FHMH, N 5 20)
and without family history of hypertension (C, N 5 18)
x2 (2 df)
Variable Kruskal-Wallis P value
RPF 5.991 0.0500
FF 0.866 .0.30
GFR 2.125 .0.30
Li-clearance 0.555 .0.30
Fractional Li excretion 0.897 .0.30
Urinary sodium excretion 1.119 .0.30
U-cGMP 0.527 .0.30
Plasma nitrate 0.043 .0.30
Urine flow 7.087 0.0289
Urinary albumin excretion 1.489 .0.30
Plasma insulin 1.615 .0.30
SBP 0.123 .0.30
DBP 3.346 0.1877
PRA 1.251 .0.30
The derivative at an arginine dose 5 7.5 for the fitted curve of each individual
was determined and could be considered as a measure of sensitivity to l-arginine.
The three groups were compared by use of the Kruskal-Wallis test with respect Fig. 1. Relationship between change in urinary sodium excretion (UNa)to sensitivity to l-arginine for each of the 14 variables. For two of the variables, and change in glomerular filtration rate (GFR) during L-arginine infu-RPF and urine flow, there was a significant difference between the groups. P ,
sion in normotensive subjects with and without a family history of0.05 was considered significant.
hypertension (N 5 55, r 5 0.40, P 5 0.003). Symbols are: (3) family
history severe hypertension (FHSH); (s) family history mild hyperten-
sion (FHMH); (m) control (C).
cGMP decreased significantly during the l-arginine infu-
sion.
ing that the l-arginine effect could be NO mediated. Com-In all subjects together, there was no significant corre-
pared with this study, higher concentrations of l-argininelation between sodium excretion and the effect of
were used in these studies, which may have stimulatedl-arginine on urinary sodium excretion.
the NO synthase, causing NO-mediated effects on theThere was, however, a significant positive relationship
kidney. In this study, we measured nitrate in plasma, whichbetween D urine flow or D urinary sodium excretion
is the main NO metabolite in vivo and has often beenand D GFR in all subjects together during infusion of
used as an index of NO formation [22, 25].l-arginine (r 5 0.40, P 5 0.003, and r 5 0.30, P 5 0.03,
The plasma level of nitrate was not increased by therespectively; Fig. 1).
l-arginine infusion in any group in this study. The use-In Figure 2, the effect of time on RPF, GFR, urinary
fulness of measuring plasma nitrate levels as an index ofsodium excretion, and fractional lithium excretion is
NO formation has been questioned because the plasmashown. No change in any parameter could be seen during
level may not accurately reflect NO production (and par-the entire study period.
ticularly not NO that is active hemodynamically).
Some effects of NO are mediated by the formation of
DISCUSSION a second messenger, cGMP [2], and accordingly, the
The results from this study demonstrate that the infu- formation of cGMP may reflect NO activity. In this study,
sion of l-arginine in normotensive subjects caused an the excretion rate of cGMP was unaffected by the
enhanced urinary albumin and sodium excretion and a l-arginine infusion. Because this is also a questionable
slight decrease in GFR. In subjects with a family history measure of NO, it is not excluded that the effects re-
of mild hypertension, a similar pattern of renal response ported were NO-mediated, especially as the l-arginine
to l-arginine infusion was noted, but in subjects with concentrations used were somewhat lower as compared
a family history of severe hypertension, the effect of with previous studies.
l-arginine infusion on urine flow rate was less pro- l-Arginine infusion, however, did not increase GFR
nounced. The time control study showed that renal he- and RPF in all studies performed. Ebel et al reported
modynamics and sodium excretion were stable during no effect of l-arginine on RPF in hypertensives and
the entire study period. in normal human subjects [10], and Barri and Wilcox
In some previous studies in animals and humans [7, 9, detected no significant effect by l-arginine infusion on
24], l-arginine infusion caused an increase in GFR and BP, GFR, or RPF in normal subjects [26]. In some stud-
RPF in addition to an enhanced natriuresis. ies, a pronounced increase in urinary sodium excretion
was seen after l-arginine infusion, for example, a tenfoldIn these studies, plasma nitrate or cGMP rose, indicat-
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because an increase in urinary sodium excretion after
l-arginine was seen in the absence of an increase or even
a reduction in GFR. This tubular effect by l-arginine
was presumably brought about by an effect on tubular
reabsorption in the proximal tubule because lithium
clearance increased significantly after l-arginine. In this
context, it could be of interest to mention Tack et al’s
study, which demonstrated that amino acid infusion dis-
rupted glomerular-tubular balance in human subjects be-
cause of nonproportional changes in GFR and renal tu-
bular reabsorption [27]. The inability of the kidneys to
respond appropriately during the l-arginine infusion
with respect to diuresis and natriuresis in subjects with
a family history of severe hypertension may have a rela-
tionship to the tubuloglomerular feedback mechanism,
which has been reported to exhibit increased sensitivity
in at least one experimental model of hypertension [28].
Our finding of a slightly but significantly less profound
effect of l-arginine on urine flow rate and to some extent
on sodium excretion in subjects with a family history
of severe hypertension extends the demonstration of a
decreased response to l-arginine with respect to renal
hemodynamics in patients with mild hypertension and
also in patients with salt sensitive hypertension [7, 9]. In
the study by Barri and Wilcox, the l-arginine effect on
urinary sodium excretion depended on salt intake in such
a way that l-arginine enhanced tubular sodium reabsorp-
tion during low salt intake and inhibited it during high
salt intake [26]. In this study, no significant relationship
between baseline sodium excretion and the effect of
l-arginine on tubular reabsorption was noted. The sig-
nificant relationship between the D GFR and D sodium
excretion during the l-arginine infusion in this study may
indicate that the renal tubular action of l-arginine was
a primary effect and that the reduction in GFR occurred
secondary to this effect.
Another effect of l-arginine, which probably has its
origin in the renal proximal tubule, is the effect on uri-
nary albumin excretion. In this study, there was an in-
crease in urinary albumin excretion with the highest
l-arginine concentration. Mogensen and Sølling more
than 20 years ago showed that an injection of amino
acids with a positively charged group, located terminally
in the molecule, proved to inhibit tubular protein reab-
sorption [29]. This finding was extended in 1983 when
Zager et al demonstrated that an injection of cationic
amino acids (lysine and arginine) induced significant re-
Fig. 2. Time control of renal plasma flow (RPF), glomerular filtration ductions in GFR and an increase in urinary albumin
rate (GFR), urinary sodium excretion (UNa), and fractional lithium excretion [30]. The amino acid-treated animals, in addi-excretion during an infusion of sodium chloride (N 5 5).
tion, had histological changes consistent with mild tubu-
lar injury compared with control rats.
In this study, urinary albumin increased five times dur-increase in urinary sodium excretion in the study by Qiu
et al, favoring not only a renal vascular but also a renal ing infusion of the highest concentration of l-arginine,
with no difference between the three groups.tubular action of l-arginine [24].
The results of this study lend support to that concept In a previous study, a significant depression of PRA
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